Pharmaceutical companies Eli Lilly and Takeda are facing a class-action lawsuit over their diabetes drug Actos, which has been certified by a California Federal Judge. The case claims that the drug was marketed without disclosing its risk of bladder cancer, with plaintiffs alleging that both companies misled the FDA about Actos' mechanism to conceal aspects of the drug's safety profile. A National Third-Party Payer Class has been granted certification consisting of thousands of TPPs who reimbursed patients for Actos between July 1, 1999 and September 17, 2010. However, lack of convincing evidence led to refusal in certifying a California Consumer Class representing all consumers in the state who paid or incurred costs related to Actos. Both parties have been directed to agree on a case schedule by June 16.
Keywords: Eli Lilly, Takeda, class-action lawsuit, Actos diabetes drug
Additional sentences:
-Actos is used to improve glycemic control in adults with Type 2 diabetes.
-The FDA review ended in June 2011 found prolonged use (lasting for more than one year) could aggravate bladder cancer risks.
-The $9 billion jury ruling was reduced eventually; Takeda settled lawsuits around $2.4 billion in April 2015